Profile Response Detail

Molecular Profile Unknown unknown
Therapy Brentuximab vedotin + Dacarbazine + Doxorubicin + Vinblastine
Indication/Tumor Type Hodgkin's lymphoma
Response Type not applicable
Create By tyin
Update By spatt

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown Hodgkin's lymphoma not applicable Brentuximab vedotin + Dacarbazine + Doxorubicin + Vinblastine FDA approved Actionable In a Phase III trial that supported FDA approval, Adcetris (brentuximab vedotin) in combination with Deticene (dacarbazine), Adriamycin (doxorubicin), and Velban (vinblastine) resulted in an improved modified progression-free survival rate of 82.1% compared to 77.2% with the combination of Adriamycin (doxorubicin), Blenoxane (Bleomycin), Velban (vinblastine) and Deticene (dacarbazine) (HR=0.77, p=0.04) in patients with untreated stage III or IV Hodgkin's lymphoma (PMID: 29224502; NCT01712490). 29224502
PubMed Id Reference Title Details
(29224502) Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma. Full reference...